CClinicalTrials.gg
CompletedNCT04675580Updated Aug 2, 2022

Telehealth Language Intervention for Children With Autism Ages 2-4 Years

An interventional study of Toy Talk in Autism Spectrum Disorder, sponsored by Weill Medical College of Cornell University. Completed at 1 site in United States. Open to participants aged 2 Years to 4 Years. Per ClinicalTrials.gov, last updated 2022-08-02.

Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
2 Years to 4 Years
Sex
All
01

Study summary

The main goal of this intervention is to increase caregivers' use of interactive play and communication strategies to improve the child's early sentence development using telemedicine and video-based feedback.

Read the detailed description

Record was updated 11/2/2021 to include more detailed information about outcome measure time points. Specifically, secondary outcome measures will be collected more frequently over the course of the study (i.e., at baseline [before starting intervention], immediate follow-up [week 12], and long-term follow-up [3 months after intervention] assessments). No changes were made to outcome measures or how they are operationalized.

02

Conditions studied

  • Autism Spectrum Disorder
03

In context

Autism Spectrum Disorder

1,727 studies on the registry are indexed under Autism Spectrum Disorder; 504 are open to participants now.

This study's enrollment of 14 is below the median of 52 across 1,371 interventional studies indexed under Autism Spectrum Disorder.

Browse Autism Spectrum Disorder studies →

Lead sponsor

Weill Medical College of Cornell University is the lead sponsor of 867 studies on the registry; 160 are open to participants now.

Of its 119 completed or terminated interventional studies of FDA-regulated products, 91 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 4 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of autism spectrum disorder (ASD) and/or communication disorder
  • Child speaks at least 50 single words or uses emerging word combinations
  • Caregivers have Internet availability from their home

Exclusion criteria

Exclusion Criteria:

  • Child speaks using complex sentences
  • Child is not within 2 to 4 years of age at time of enrollment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Tele Toy Talk

    Caregivers of child participants receive 1-hour of telemedicine featuring parent-mediated naturalistic developmental behavioral intervention weekly for 10 weeks.

    Behavioral: Toy Talk

  • No intervention
    Multiple Baseline

    Prior to receiving the intervention, participants will be randomized into one of three baseline conditions: a three-, four-, or five-week baseline period. At each weekly baseline session, caregivers will record the Tele-BOSCC (see Outcomes Measures section).

Interventions

  • BehavioralToy Talk

    Language modeling strategy encouraging caregivers to (1) talk about the toys the child is playing with, including the states, actions, and properties of the toys and (2) give the object its name using a lexical noun phrase.

06

What researchers measure

Primary outcomes

  1. Change in number of unique combinations of subjects and verbs - caregiver

    Number of unique combinations of subjects and verbs used by the caregiver at baseline, intervention midpoint, and post-evaluation. This will be calculated by transcribing 12-minute language samples from the BOSCC using Systematic Analysis of Language Transcripts (SALT) software.

    Time frame: Baseline (Before starting intervention); Week 4; Week 8; Week 12

  2. Change in number of unique combinations of subjects and verbs - child

    Number of unique combinations of subjects and verbs used by the child at baseline, intervention midpoint, and post-evaluation. This will be calculated by transcribing 12-minute language samples from the BOSCC using Systematic Analysis of Language Transcripts (SALT) software.

    Time frame: Baseline (Before starting intervention); Week 4; Week 8; Week 12

  3. Change in caregiver mean length of utterance

    Mean length of utterance used by caregiver at baseline, intervention midpoint, and post-evaluation. This will be calculated by transcribing 12-minute language samples from the BOSCC using Systematic Analysis of Language Transcripts (SALT) software.

    Time frame: Baseline (before starting intervention); Week 4; Week 8; Week 12

  4. Change in child mean length of utterance

    Mean length of utterance used by child at baseline, intervention midpoint, and post-evaluation. This will be calculated by transcribing 12-minute language samples from the BOSCC using Systematic Analysis of Language Transcripts (SALT) software.

    Time frame: Baseline (before starting intervention); Week 4; Week 8; Week 12

  5. Change in Brief Observation of Social Communication Change (BOSCC) scores

    Child's scores on the Brief Observation of Social Communication Change (BOSCC) at baseline, intervention midpoint, and post-evaluation. BOSCC scores are not linear. Each item is rated on a 6-point scale from 0 (abnormality is not present) to 5 (abnormality is present and significantly impairs functioning).

    Time frame: Baseline (before starting intervention); Week 4; Week 8; Week 12

Secondary outcomes

  1. Change in scores on the Observation of Spontaneous Expressive Language (OSEL) - baseline

    Child's scores on the Observation of Spontaneous Expressive Language at baseline, post-evaluation, and long-term follow-up evaluation (3 months after ending intervention). Scores on the OSEL are not linear. Scores range from 0 to 3, with higher scores indicating more impairment.

    Time frame: Baseline (before starting intervention); Week 12; Follow-up assessment (3 months after end of intervention)

  2. Change in scores on the Vineland-3

    Scores on the Vineland-3 at baseline, post-evaluation, and long-term follow-up evaluation (3 months after ending intervention). The Vineland-3 provides norm-referenced scaled scores for 11 skill areas (M = 10; SD = 3) as well as standard scores (M =100, SD = 15) for three adaptive domains.

    Time frame: Baseline (before starting intervention); Week 12; Follow-up assessment (3 months after end of intervention)

Other outcomes

  1. Change in scores on the Acceptance and Action Questionnaire, Second Version (AAQ-II)

    Caregiver scores on the Acceptance and Action Questionnaire, Second Version (AAQ-II) at baseline, post-evaluation, and long-term follow-up evaluation (3 months after end of intervention). Items are rated on a Likert-type scale of 1 through 7, and scores range from 7 to 49.

    Time frame: Baseline (before starting intervention); Week 12; Follow-up assessment (3 months after end of intervention).

  2. Change in scores on the Emotion Regulation Questionnaire (ERQ)

    Caregiver scores on the Emotion Regulation Questionnaire (ERQ) at baseline, post-evaluation, and long-term follow-up evaluation (3 months after ending intervention). The ERQ is a 10-item scale with each item consisting of a 7-point Likert-type scale ranging from 1 to 7.

    Time frame: Baseline (before starting intervention); Week 12; Follow-up assessment (3 months after end of intervention).

  3. Change in scores on the Caregiver Strain Questionnaire - Short Form 7 (CSQ-SF 7)

    Scores on the Caregiver Strain Questionnaire - Short Form 7 (CSQ-SF 7) at baseline, post-evaluation, and long-term follow-up evaluation (3 months after ending intervention). The CSQ-SF7 contains seven items, with response options on a five-point Likert-type scale.

    Time frame: Baseline (before starting intervention); Week 12; Follow-up assessment (3 months after end of intervention).

  4. Change in scores on the Parent Stress Index-4th Edition (PSI-4)

    Scores on the Parent Stress Index (PSI-4) at baseline, post-evaluation, and long-term follow-up evaluation (3 months after ending intervention). The PSI-4 is a 120-item inventory that provides two domain scores that are quantified using T scores (mean of 50; standard deviation of 10).

    Time frame: Baseline (before starting intervention); Week 12; Follow-up assessment (3 months after end of intervention).

07

Study locations

1 site
  • Center for Autism and the Developing Brain/New York-Presbyterian Hospital
    White Plains, New York 10605, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04675580
Lead sponsor
Weill Medical College of Cornell University
Responsible party
Sponsor
First posted
Dec 19, 2020
Start date
Dec 23, 2020
Primary completion
Jul 15, 2022
Completion
Jul 15, 2022
Last update
Aug 2, 2022

Study contacts

So Hyun Kim, Ph.D.
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion